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Rhabdomyosarcomas of the parotid and submandibular glands have the histological appear-
ance of a skeletal muscle tumor yet can be found in tissue with no striated muscular ele-
ments.We examine the potential cell-of-origin for rhabdomyosarcoma and whether salivary
tumors represent primary malignancy or metastasis.We have previously established genet-
ically engineered mouse models of rhabdomyosarcoma. In these mice, rhabdomyosarcoma
is only induced when a Pax3:Foxo1 fusion oncogene is activated with concurrent loss of
p53 function (for alveolar rhabdomyosarcoma) or loss of p53 function alone (for embry-
onal rhabdomyosarcoma) using Cre-lox technology. These mutations are only activated
under the control of promoters specific for selected cell lineages, previously thought to be
myogenesis-restricted. RT-PCR and immunohistochemistry for lineage-specific promoter
gene products reveal these promoters are active in wild-type mouse salivary gland. Given
that mouse rhabdomyosarcoma frequently originates in the salivary glands and these
myogenic-related promoters are normally expressed in salivary tissue, a high likelihood
exists that the salivary gland contains a cell-of-origin of this muscle-related cancer.
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INTRODUCTION
Rhabdomyosarcomas (RMS) of the parotid and submandibular
glands are the most lethal forms of salivary gland malignancy in
children (1). An analysis of the surveillance, epidemiology, and
end results (SEER) database from 1988 to 2001 of parotid or sub-
mandibular tumors in patients under 18 years old revealed that
8% tumors were RMS, yet RMS accounted for the majority of
salivary malignancy related deaths (1). Salivary gland RMS are of
the embryonal subtype (eRMS, 66%), the alveolar subtype (aRMS,
20%), or rarer histologies (2). Seventy percent of aRMS harbor the
t (2;13) balanced translocation that creates the Pax3:Foxo1 fusion
oncogene (3). In eRMS, no single driving oncogenic mutation has
been identified although p53 loss of function is common (4). The
salivary glands are also known sites of metastasis for RMS (2).
This epidemiology begs the question, is an isolated parotid or sub-
mandibular gland RMS a primary salivary gland malignancy, local
invasion, or metastasis?
MATERIALS AND METHODS
ANIMAL STUDIES
All studies were performed under institutional Oregon Health &
Science University IACUC approval. All mouse lines have been
previously described (4, 5).
HISTOLOGY AND IMMUNOHISTOCHEMISTRY STUDIES
The tissue samples were harvested after euthanasia and treated
with CRYO-GEL Embedding Medium (Cancer Diagnostics),
rapidly frozen in precooled 2-methylbutane (Sigma), and stored at
−80°C. For hematoxylin and eosin staining, frozen sections were
fixed in 10% formalin for 10 min and were rinsed in distilled water
three times then stained with hematoxylin and eosin as previously
described (5). For immunostaining, frozen sections were fixed by
cold methanol at −20°C and then processed for Pax7 and Myf6
staining as suggested in the manufacturer’s protocol (PK2200, SK
4105, Vector Laboratories and PI-1000, SK 4105, Vector Laborato-
ries, respectively). The anti-Pax7 antibody (Developmental Studies
Hybridoma Bank, Iowa City, IA, USA) was used at 1:50 dilution,
and the Myf6 antibody (Developmental Studies Hybridoma Bank,
Iowa City, IA, USA) was used at 1:200 dilution. Sections were
counterstained with hematoxylin. Normal mouse skeletal muscle
section was used as the positive control, whereas muscle sections
without primary antibody (e.g., secondary only) was set as the
negative control.
RNA ISOLATION AND QUANTITATIVE RT-PCR
Total RNA isolation, cDNA synthesis and RT-PCR for Pax7, Myf5,
and Myf6 in various mouse organs was performed as described
previously (6). The relative expression of Pax7, Myf5, and Myf6
was determined by quantitative RT-PCR using Taqman primer
and probesets (mouse Pax7 -Mm00834032_m1, mouse Myf5-
Mm00435125_m1, and mouse Myf6-Mm00435126_m1) on a
StepOnePlus™ Realtime PCR system from Applied Biosystems.
RESULTS
We have previously created and characterized genetically engi-
neered mouse models (GEMMs) of aRMS and eRMS that are
representative of the human diseases and may shed light on the
origin of salivary RMS (Figure 1A) (3, 4). In our GEMMs, events
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FIGURE 1 | (A) Mouse models of salivary gland rhabdomyosarcoma. Top
row, representative gross photograph and histologic examination of a
mouse parotid embryonal rhabdomyosarcoma: inset, desmin
immunohistochemistry. Lower row, representative gross photograph and
histologic examination of a mouse submandibular alveolar
rhabdomyosarcoma. Scale bar, 50µm. (B) Conditional alleles for
rhabdomyosarcoma mouse models. The Cre-LoxP recombination is utilized
to activate mutations necessary for RMS tumorigenesis. (i) LoxP sites are
inserted on either side of p53. Cre recombinase enzyme can then splice out
and inactivate (conditionally knock-out) this tumor suppressor gene. (ii) LoxP
sites are placed between Pax3 and an artificially embedded 3′ Foxo1 gene
fragment for this conditional knock-in. Cre can then remove the intervening
DNA and generate the Pax3:Foxo1 fusion oncogene. (iii) Cre recombinase
expression is under the control of lineage-specific promoters Pax7, Myf5,
and Myf6. (C) Expression of myogenic markers in the salivary gland. RT-PCR
reveals strong Pax7, Myf5, and Myf6 expression in the salivary glands and
skeletal muscle satellite cells (but not myotube nuclei), and not in renal
tissue. (D) Diagrammatic representation of major cell types of the salivary
gland. (E) Immunohistochemistry of Pax7 in muscle (top left panel)
demonstrates strong expression in the skeletal muscle satellite cell nuclei
(brown nucleus, upper arrowhead) but not myotube nuclei (non-brown
nucleus, lower arrowhead). The submandibular gland also show numerous
cells staining positive for Pax7 (bottom left panel; 10µM scale bar) and Myf6
(right bottom panel; 50µm scale bar). Myf6+ cells are numerous (yellow
arrowheads); however, in the inset a selected slender myoepithelial cells is
Myf6 negative (white arrowhead). Abbreviations: eRMS, embryonal
rhabdomyosarcoma; aRMS, alveolar rhabdomyosarcoma; SMG,
submandibular gland, RMS, rhabdomyosarcoma; RQ, relative quantification;
ND, no detectable expression; KID, kidney; SKM, skeletal muscle; PG,
parotid gland; MEC, myoepithelial cell.
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activating Pax3:Foxo1 and/or turning off p53 are spatially and
temporally restricted to a chosen cell lineage by Cre-Lox recom-
bination (Figure 1B). aRMS is only produced if the Pax3:Foxo1
fusion oncogene is activated with a concurrent loss of p53 func-
tion (3). Embryonal RMS requires inactivation of p53 alone (4).
Our mice develop histologically and clinically analogous tumors
to the human diseases, and RMS arises from the submandibular
or parotid gland in 20% of their tumors (for aRMS and eRMS
equivalently).
Historically, we had chosen to express Cre-Lox under promot-
ers active in muscle development and postnatal muscle, namely
Pax7, Myf5, and Myf6 (Figure 1Biii), based on the observation
that RMS is a malignancy with a muscle-related histopathology.
A Pax7-Myf5-Myf6 ontogeny is found in a surprising variety of
tissues, including not only skeletal muscle but also the pituitary
(5–8). In the case of muscle, Pax7+ stem cells (also called satel-
lite cells) remain quiescent until activated, then express Myf5 and
divide asymmetrically producing Myf6 expressing myoblast inter-
mediate progenitors, which later become terminally differentiated
non-dividing myotubes (5, 8). The related but distinct pituitary
ontogeny was first described by our laboratory, whereby Nestin
expressing pituitary stem cells give rise to Pax7+ intermediate
progenitors, which become Myf6+ terminally differentiated cor-
ticotrophs (7). Thus, a Pax7-Myf5-Myf6 ontogeny exists in both
muscle and pituitary, but Pax7 is not always expressed in the stem
cell (Pax7 can be shifted down in the ontogeny). The most interest-
ing aspect of our studies was that Myf6+ terminally differentiated
corticotrophs could have ongoing cell division, which is not seen
in terminally differentiated myotubes (7). Given the frequency of
salivary RMS in our mouse models, we speculated – and then
found the evidence below – that the Pax7-Myf5-Myf6 ontogeny is
also found in native salivary cells, which would logically predispose
this tissue to rhabdomyosarcomagenesis.
Development of the mouse submandibular gland begins at
E11.5 and continues beyond E15 (9). Embryonically, the major-
ity of submandibular gland mesenchymal cells are derived from
the Wnt1-derived cranial neural crest but whether these cra-
nial neural crest cells share expression of Pax3, Pax7, or Myf6
remains yet unexplored (10). In the mature submandibular gland
(Figure 1D), well-differentiated myoepithelial cells have ongoing
mitotic division (11) – making these cells a potential candidate
for transformation. Mesoangioblasts are present in fetal (and to a
lesser extent adult) large and small blood vessels, and have the plas-
ticity to become/repair skeletal muscle (12). Interestingly, these
mesoangioblasts express Pdgfra (12), which is also a marker of
the developing cranial neural crest derived submandibular gland
mesenchyme and a key factor in ductal branching morphogen-
esis (10). Thus, our hypothesis became that the cell-of-origin
for rhabdomyosarcoma in the salivary gland is a myoepithelial
cell, a mesoangioblast, a retained primitive prenatal mesenchy-
mal cell – or perhaps a salivary cell subtype that is terminally
differentiated but comes out of quiescence following transforma-
tion. This hypothesis is supported by our findings that many cell
types of the adult salivary glands are sometimes Pax7+ and very
broadly Myf6+ (Figures 1C,E). For these studies, we performed
RT-PCR and immunohistochemistry on mouse submandibular
gland tissue of wild-type mice (not harboring any mutation).
RNA expression of Pax7, Myf5, and Myf6 transcription factors
is present in parotid and submandibular gland tissue (Figure 1C).
The expression levels of these factors are similar to skeletal mus-
cle. The negative control of the kidney tissue gives reassurance
that these transcription factors are not constitutively active in all
tissue. By immunohistochemistry (Figure 1E),Pax7 and Myf6 are
expressed in multiple cell types throughout normal mouse salivary
gland tissue including serous demilune cells, mucous cells, and
intercalated duct cells – but, surprisingly, not always in myoep-
ithelial cells (Figure 1E white arrowhead). Given that 20% of our
mouse RMS tumors originate in the salivary gland and that this tis-
sue inherently utilizes the lineage-specific promoters, which yield
aRMS and eRMS, a high likelihood exists that one or more subtype
of native salivary cells themselves may represent the cell-of-origin
of these tumors.
DISCUSSION
While our data do not provide definitive evidence that native sali-
vary gland tissue hosts the cell-of-origin for salivary RMS, we do
show that the lineages needed to cause mouse RMS are present
and actively expressed within salivary tissue. The belief that sali-
vary RMS is the result of metastasis or local invasion might not
always be the case. To this end, RMS can also be viewed as a tumor
of primitive mesenchyme, which demonstrates a tendency toward
myogenesis (13). Cell types of interest for prioritized future stud-
ies include myoepithelial cells, mesoangioblasts, and/or retained
primitive prenatal mesenchymal cells. Interestingly, primary syn-
ovial sarcomas, which can be induced experimentally in mice
under a Myf5 promoter (14), have been reported in the human
pancreas (15) – another exocrine gland. Future studies will address
the salivary cell subtypes belonging to the Pax7, Myf5, and Myf6
lineages, timing of tumor initiation, and the potential stem-cell like
plasticity of this ontogeny. A great deal remains to be learned about
the cell-of-origin of rhabdomyosarcoma and other cancers; how-
ever, given that the cell-of-origin for a tumor determines tumor
cell phenotype and possibly treatment paradigms (16), we may
soon be empowered by new tools targeting the epigenetic memory
of tumors.
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